ipilimumab + placebo

Ipilimumab + placebo refers to the control arm of a Phase II randomized, double-blind clinical trial (Study 007) conducted by Bristol Myers Squibb and Medarex. In this study, patients with previously treated unresectable Stage III or IV malignant melanoma received ipilimumab (10 mg/kg) in combination with a placebo to determine the baseline incidence of grade 2-4 diarrhea, a common immune-related adverse event. This arm served as the comparator for a group receiving ipilimumab plus prophylactic oral budesonide. Ipilimumab is a fully human monoclonal antibody that inhibits CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), a negative regulator of T-cell activity. By blocking CTLA-4, ipilimumab enhances the immune system's ability to recognize and destroy cancer cells. The placebo component in this specific trial arm was used as a control for budesonide, not for ipilimumab itself.

Brand names

Yervoy

Other names

Ipilimumab + Placebo